Clinical Role of Newly Developed ALBI and mALBI Grades for Treatment of Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is a leading cause of death worldwide. The selection of therapeutic modalities and the prognosis of affected patients are well known to be dependent not only on the tumor burden but also on the hepatic reserve function. Antiviral treatments for chronic hepatitis relate...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-10-01
|
| Series: | Applied Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-3417/10/20/7178 |
| _version_ | 1797550940647063552 |
|---|---|
| author | Atsushi Hiraoka Takashi Kumada |
| author_facet | Atsushi Hiraoka Takashi Kumada |
| author_sort | Atsushi Hiraoka |
| collection | DOAJ |
| description | Hepatocellular carcinoma (HCC) is a leading cause of death worldwide. The selection of therapeutic modalities and the prognosis of affected patients are well known to be dependent not only on the tumor burden but also on the hepatic reserve function. Antiviral treatments for chronic hepatitis related to a viral infection and an increase in cases of nonviral HCC associated with the aging of society have resulted in dramatic changes regarding the characteristics of HCC patients. With recent developments in therapeutic modalities for HCC, a more detailed assessment of hepatic function has become an important need. Studies in which the relationship of albumin-bilirubin (ALBI) grade with the prognosis of HCC patients was investigated were reviewed in order to evaluate the usefulness of newly developed ALBI and modified ALBI (mALBI) grades for HCC treatment, as those scoring methods are considered helpful for predicting the prognosis and selecting therapeutic modalities based on the expected prognosis. |
| first_indexed | 2024-03-10T15:36:34Z |
| format | Article |
| id | doaj.art-85b9c2674f834385bfa05454e61f5641 |
| institution | Directory Open Access Journal |
| issn | 2076-3417 |
| language | English |
| last_indexed | 2024-03-10T15:36:34Z |
| publishDate | 2020-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Applied Sciences |
| spelling | doaj.art-85b9c2674f834385bfa05454e61f56412023-11-20T17:10:09ZengMDPI AGApplied Sciences2076-34172020-10-011020717810.3390/app10207178Clinical Role of Newly Developed ALBI and mALBI Grades for Treatment of Hepatocellular CarcinomaAtsushi Hiraoka0Takashi Kumada1Gastroenterology Center, Ehime Prefectural Central Hospital, Kasuga-cho 83, Ehime 790-0024, JapanDepartment of Nursing, Gifu Kyoritsu University, Gifu 503-8550, JapanHepatocellular carcinoma (HCC) is a leading cause of death worldwide. The selection of therapeutic modalities and the prognosis of affected patients are well known to be dependent not only on the tumor burden but also on the hepatic reserve function. Antiviral treatments for chronic hepatitis related to a viral infection and an increase in cases of nonviral HCC associated with the aging of society have resulted in dramatic changes regarding the characteristics of HCC patients. With recent developments in therapeutic modalities for HCC, a more detailed assessment of hepatic function has become an important need. Studies in which the relationship of albumin-bilirubin (ALBI) grade with the prognosis of HCC patients was investigated were reviewed in order to evaluate the usefulness of newly developed ALBI and modified ALBI (mALBI) grades for HCC treatment, as those scoring methods are considered helpful for predicting the prognosis and selecting therapeutic modalities based on the expected prognosis.https://www.mdpi.com/2076-3417/10/20/7178albumin-bilirubin (ALBI) grademodified ALBI gradehepatocellular carcinomamolecular targeting agentresectionradiofrequency ablation |
| spellingShingle | Atsushi Hiraoka Takashi Kumada Clinical Role of Newly Developed ALBI and mALBI Grades for Treatment of Hepatocellular Carcinoma Applied Sciences albumin-bilirubin (ALBI) grade modified ALBI grade hepatocellular carcinoma molecular targeting agent resection radiofrequency ablation |
| title | Clinical Role of Newly Developed ALBI and mALBI Grades for Treatment of Hepatocellular Carcinoma |
| title_full | Clinical Role of Newly Developed ALBI and mALBI Grades for Treatment of Hepatocellular Carcinoma |
| title_fullStr | Clinical Role of Newly Developed ALBI and mALBI Grades for Treatment of Hepatocellular Carcinoma |
| title_full_unstemmed | Clinical Role of Newly Developed ALBI and mALBI Grades for Treatment of Hepatocellular Carcinoma |
| title_short | Clinical Role of Newly Developed ALBI and mALBI Grades for Treatment of Hepatocellular Carcinoma |
| title_sort | clinical role of newly developed albi and malbi grades for treatment of hepatocellular carcinoma |
| topic | albumin-bilirubin (ALBI) grade modified ALBI grade hepatocellular carcinoma molecular targeting agent resection radiofrequency ablation |
| url | https://www.mdpi.com/2076-3417/10/20/7178 |
| work_keys_str_mv | AT atsushihiraoka clinicalroleofnewlydevelopedalbiandmalbigradesfortreatmentofhepatocellularcarcinoma AT takashikumada clinicalroleofnewlydevelopedalbiandmalbigradesfortreatmentofhepatocellularcarcinoma |